Connect your AI

King Pharmaceuticals KG Less than 12 Months

Other financials

Income statement

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

Operating cash flow-$15.1M-1,628%

Valuation

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

Net margin131.5%—

Returns & leverage

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept kg:FixedMaturitiesContinuousUnrealizedLossPositionLessthanTwelveMonthsFairValue.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's less than 12 months.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is King Pharmaceuticals's less than 12 months?: King Pharmaceuticals (KG) reported less than 12 months of $90.76M in Q1 2026.